Insilico Medicines first AI discovered antifibrotic drug goes first in human

Insilico Medicine today announced that the first healthy volunteer has been dosed in a firstinhuman microdose trial of ISM001055. ISM001055 is a potentially firstinclass small molecule inhibitor of a novel biological target discovered by Insilico Medicines endtoend AIpowered drug discovery platform. It is being developed for the treatment of idiopathic pulmonary fibrosis (IPF), a chronic lung disease which results in progressive and irreversible decline in lung function.